advancing innovation to save lives

GHTC fact sheet looks at role of R&D in advancing universal health coverage

GHTC released a new fact sheet examining how R&D of new drugs, vaccines, diagnostics, and other tools is a critical driver of universal health coverage. The resource looks at out how new and improved technologies can help expand access to care in low-resource communities, fill urgent treatment and prevention gaps to improve quality of care, overcome barriers to care among vulnerable populations, and generate health care system cost savings.
View

GHTC unveils new report on global health innovation at USAID

GHTC unveiled a new report examing how the US Agency for International Development’s (USAID) investments in global health innovation are an essential enabler in accelerating partner countries along the journey to self-reliance. It explores challenges and opportunities the agency faces in advancing this work and provides actionable recommendations for the administration and Congress to maximize the agency's health research and development activities.
View

Member Spotlight: Medicines for Malaria Venture

MMV is a leading product development partnership in antimalarial drug research celebrating its 20th anniversary in November. Since foundation in 1999, MMV and partners have developed and brought forward eleven new medicines estimated to have saved 1.9 million lives from malaria.

Learn More

GHTC works to save and improve lives by encouraging the research and development of essential health technologies. We bring together more than 25 nonprofit organizations, academic institutions, and aligned businesses to advance policies to accelerate the creation of new drugs, vaccines, diagnostics, and other tools that bring healthy lives within reach for all people.

Why we're needed

Health technologies have the potential to save millions of lives. New tools are needed to slow the global threat of diseases, including HIV/AIDS, malaria, tuberculosis, and neglected tropical diseases, and tackle many other pressing health needs. For diseases and conditions primarily affecting people in the world’s poorest places, there is little to no commercial market to spur R&D. Strong investment and innovative solutions are needed to catalyze the development of new technologies to bring health and opportunity within reach for all people.

Learn more

PATH/Matthew Dakin
GHTC sends FY21 letter to OMB

GHTC sent a letter to the White House Office of Management and Budget (OMB), calling for the administration to sustain and protect global health R&D in the fiscal year 2021 (FY21) budget.

PDF

PATH/Matthew Dakin
GHTC op-ed featured in The Hill

A commentary piece authored by GHTC Director Jamie Bay Nishi on the steady and substantial funding necessary to drive breakthrough innovations for global health threats was featured in The Hill

View
View All News & Events

Community Event

PATH/Gabe Bienczycki
World Health Summit 2019
World Health Summit
Learn More

Community Event

PATH/Eric Becker
World Infectious and Rare Diseases Congress
Scientific Future Group
Learn More
View All Events
Medicines for Malaria Venture
Saving two lives, not just one: medicines for malaria during pregnancy

An estimated 125 million pregnancies around the world are at risk from malaria annually. For both mother and baby, the disease is potentially life-threatening and babies that do survive are often born with low birth weight, which is associated with negative impact on development.

Read More
PATH/Georgina Goodwin
Research Roundup: An experimental Ebola cure may also protect against Nipah virus, gender inequality in clinical trials, and FDA authorizes first Zika diagnostic test for marketing

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

Read More
View Breakthroughs Blog

Our members work to improve health worldwide